The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Risedronate Mylan Once a Week 35mg film-coated tablets

35 milligram(s) Film-coated tablet

McDermott Laboratories Ltd t/a Gerard LaboratoriesPA0577/127/001

Main Information

Trade NameRisedronate Mylan Once a Week 35mg film-coated tablets
Active SubstancesRisedronate sodium hemipentahydrate
Strength35 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderMcDermott Laboratories Ltd t/a Gerard Laboratories
Licence NumberPA0577/127/001

Group Information

ATC CodeM05BA Bisphosphonates
M05BA07 risedronic acid


Licence Issued26/11/2010
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0068-124-003
Interchangeable List DocumentPDF of Interchangeable List
« Back